Positioning versus price structure: the women’s-health wrapper against the single flat number.
The two models
Hers is Hims’ women-focused sibling, sharing the platform, the post-Novo compounded “personalization” posture, and the aggressive entry pricing — wrapped in women’s-health positioning. The same questions apply: maintenance-dose truth, fee stack, and legal lane, all pending verification in our queue.
Henry Meds advertises the market’s best-known flat-rate compounded pricing — a structure we favor on principle, because flat rates make teaser math impossible. Whether the advertised flat number survives contact with membership terms, shipping, and dose realities is precisely what its pending verification pass will establish; until then, no Henry figure is published here.
Verified vs pending — read this before the marketing
Neither provider on this page has completed price verification, so this comparison stays structural — business models, pricing architecture, and the questions each must answer — with zero advertised numbers repeated as facts. The only verified figures on this site today sit in the ledger.
What the wrapper costs, what the number hides
Hers asks you to value brand fit; Henry asks you to value arithmetic. The diligence inverts accordingly: for Hers, unwrap to the medication facts — pharmacy, product, maintenance total; for Henry, stress-test the flat number’s edges — terms, shipping, cancellation. Two different audits, one shared status: pending verification, zero repeated claims, and the calculator ready for whichever quotes you extract.
Go deeper
Full files: Hers · Henry Meds. Decision tools: the quiz routes by coverage and priorities; the calculator turns any quote into a true 12-month number; the ledger holds every verified figure and every pending slot.